AstraZeneca PLC (LON: AZN)

Market Cap	159.00B
Revenue (ttm)	38.20B
Net Income (ttm)	4.85B
Shares Out	1.55B
EPS (ttm)	3.10
PE Ratio	33.12
Forward PE	14.13
Dividend	2.34 (2.28%)
Ex-Dividend Date	Aug 8, 2024

Volume	3,826,293
Open	10,222
Previous Close	10,244
Day's Range	10,084 - 10,280
52-Week Range	9,461 - 13,388
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD